Partners Innovation Fund

Partners Innovation Fund provides the necessary support to advance innovations in medical systems, therapy, drugs and medical devices.

Business Model: Non-Profit

Revenue: $0

Employees: 0-0

Rankings

Detailed Partners Innovation Fund Information

Geographic Data

Partners Innovation Fund headquarters map

Address: 215 First Street Suite 500

City: Cambridge

State: MA

Zip: 02142

Country: US

Financial Info

Stage:

Raised Last:

$0

Raised Total:

$0

Metrics

0Website Global Rank

0Website Monthly Traffic

Twitter Followers

Description

The Innovation Fund was created in 2007 by Brigham and Women&s;s Hospital and Massachusetts General Hospital to address a growing unmet need for funding emerging technology in the capital gap between invention and product development. The main objective of the fund is to accelerate to market technologies developed by Partners HealthCare investigators, thereby enhancing healthcare quality, cost and outcomes. Structured as a separate LLC entity, the $35M Fund is evergreen in design and will reinvest all gains from investments back into the Fund to create capital for additional investments. Investment decision oversight is provided by an independent external committee composed of experts from industry, venture capital and academia. The Fund operates on a venture capital model whereby opportunities are rigorously evaluated on the basis of scientific strength as well as potential for commercial success. The Fund has four major goals: * Capture more value from the PHS research portfolio by creating companies, technologies and solutions that advance and enhance healthcare. * Provide funding for technologies positioned in the capital gap between invention and clinical development. * By demonstrating institutional commitment, attract external capital that will leverage and encourage co-investment. * Generate a return on investment to refresh the fund and provide capital for additional technologies. Gap Funding Over the last five to seven years, the environment for early-stage investing has undergone significant change. As a result of these changes, there is a dearth of funding support for technologies/companies positioned between invention and clinical development. By focusing on this capital gap, the Fund can advance technologies of high commercial potential and medical benefit to a stage where larger, more traditional investment sources are attracted to underwrite the risk. Types of Fund Investments The Partners Innovation Fund will make two types of investments: Equity and Development. Equity investments are seed and early financings that will catalyze company formation. These investments will often be a Series A stock and co-investors are frequently other early institutional investors, private investors or corporate investment funds. Development investments precede company formation and are intended to validate technologies with a high potential for later commercialization by either new venture formation or out-licensing to an existing market player. For all investments, funds will be reserved for participation in follow-on investments. Innovation Fund Process Utilizing a proven venture capital based diligence model, the team conducts in-depth diligence on all opportunities in two steps: 1. Initial Screening: Assesses opportunities for high commercial potential. Key project attributes are: * Product concept and value proposition * Intellectual Property Position * Stage of technology development * Market Opportunity * Technology Review * Management Team * Regulatory pathway * Funding requirements * Competitive Analysis * Business Model 2. Evaluation and Investment Decision: During this step, PIF staff conducts extensive diligence to assess the strength of the proposed business in relation to our investment criteria. This process takes place over 3 to 6 months during which time we interact with technical and market experts, possible customers, competitors and potential co-investors as we prepare for presentation of the investment opportunity to our external Investment Committee for final approval. The team will work with investigators and their advisors to develop a project or business plan including connections to potential entrepreneurs, advisors and investors in the venture, private or corporate arena. Venture Launch / Ongoing Support: Once an investment has been approved, the Innovation Fund plays an active role in the ongoing development of the new venture. The team will work on all aspects required to move the new entity forward including recruiting senior management and staff, providing guidance and support in technology development, serving on the Board of Directors and working with management to achieve milestones.

Contact Phone:
+18573072400

Contact Email:

Announced Date Company Transaction Money Raised
3/2015 Daktari Diagnostics Series D 0
7/2019 Amolyt Pharma Series A 0
2/2016 Spero Therapeutics Series B 30M
12/2013 Spero Therapeutics Seed Round -
3/2020 Keros Therapeutics Series C 0
5/2015 lifeIMAGE Venture Round 17.6M
1/2012 Translate Bio Series A 20.7M
10/2012 InStore Finance Debt Financing 125k
11/2018 Abcuro Series A 0
6/2015 Sebacia Series C 12M
6/2015 Spero Therapeutics Series A 0
3/2016 Syntimmune Series A 10M
9/2012 Annovation BioPharma Series A 8M
4/2014 Spero Therapeutics Series A 0
11/2017 Keros Therapeutics Series A 11M
7/2015 Translate Bio Series B 0
2/2021 Pykus Therapeutics Venture Round 2.5M
2/2015 Lysosomal Therapeutics Series A 20M
12/2011 Daktari Diagnostics, Inc. Series B 10M
5/2014 Lysosomal Therapeutics Seed Round 4.8M
11/2016 Syntimmune Series A 8M
6/2017 Syntimmune Series B 50M
10/2014 Raze Therapeutics Series A 24M
10/2009 Daktari Diagnostics Series A 2.8M
3/2013 QPID Health Series A 4.4M
3/2013 CoStim Pharmaceuticals Series A 22M
12/2009 lifeIMAGE Series A 2.2M
12/2011 lifeIMAGE Series B 8.1M
3/2016 ImmuneXcite Series A 8.6M
8/2018 Akouos Series A 25.1M
4/2020 SwanBio Therapeutics Series A 0
5/2017 Magenta Therapeutics Series B 0
7/2017 Sebacia Series D 0
3/2020 Akouos Series B 105M
3/2020 Affinia Therapeutics Series A 0
4/2019 Nocion Therapeutics Series A 0
4/2020 ROME Therapeutics Series A 0
10/2014 Syntimmune Series A 8M
3/2009 TargAnox Series A 5.1M
6/2009 lifeIMAGE Series A 2.7M
11/2013 Editas Medicine Series A 43M
9/2019 ZielBio Series A 25.1M
12/2019 Triplet Therapeutics Series A 49M
11/2017 Akouos Seed Round 7.5M
1/2019 Keros Therapeutics Series B 0
2/2021 Pykus Therapeutics Venture Round 0
4/2020 ROME Therapeutics Series A 0
4/2020 SwanBio Therapeutics Series A 0
3/2020 Affinia Therapeutics Series A 0
3/2020 Keros Therapeutics Series C 0
3/2020 Akouos Series B 0
12/2019 Triplet Therapeutics Series A 0
9/2019 ZielBio Series A 0
7/2019 Amolyt Pharma Series A 0
4/2019 Nocion Therapeutics Series A 0

Startup Industries

Startup Locations

Portfolio Current Status

Portfolio Employee Count

Name Price
Name Size Announced Date

You know, we could be doing all this for you..

CoBee's Logo

Be ahead of your competition

  • Realtime intelligence
  • Automated contact tracking
  • Unmatched insights
  • Eliminate manual research